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Abstract 
INTRODUCTION:  
The cerebral anomaly of a cavum septum pellucidum (CSP) has been the subject of 
controversy in neuroimaging since the hallmark study by DeGreef in 1992.  The 
association of CSP with schizophrenia and postulation of CSP as a marker of cerebral 
midline maldevelopment has been studied extensively with no consistent outcome.  The 
storm of debate underlies the requirement for a reliable objective imaging marker as an 
organic cause of mental illness. 
AIM:  
This study aims to determine the prevalence of cavum septum pellucidum in mental 
health referrals in South Africa and determine the significance thereof. 
METHOD:  
This was a retrospective, observational study based at Baragwanath Hospital, including 
114 mental health referrals and 114 controls, matched for age and sex.  The CT scans of 
these patients’ brains were anonymously reviewed by three independent 
radiologists/radiologists in training to determine the prevalence of CSP, and the length 
and width of CSP’s, if present. 
RESULTS:  
There was no statistical significance in the difference in prevalence of CSP between the 
mental health referrals and controls.  The anteroposterior length of CSP was not a 
statistically significant determinant of mental illness but an increased average axial width 
was a statistically significant measurement in the mental health referrals. 
CONCLUSIONS:  
The axial width of CSP is a statistically significant determinant of mental illness.   
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1. Literature review 
1.1. Cavum Septum Pellucidum 
1.1.1. Definition 
The septum pellucidum is a component of the limbic system, composed of two laminae 
that fuse to form a thin plate, which separates the lateral ventricles in the midline (1, 2).  
The septum pellucidum functions as a connection between the hypothalamus and 
habenular commissure, hippocampus and amygdala, as well as reticular formation of the 
brainstem (3, 4).  
Fusion of the two leaflets of the septum pellucidum occurs in 85% of individuals within 6 
months of birth, most likely due to rapid growth of the hippocampus and corpus callosum 
(2, 5).  If the laminae fail to fuse, a residual cavity remains, termed a cavum septum 
pellucidum (1, 2, 6, 7).  A CSP has been postulated to serve as a marker of disturbed brain 
development (2, 5), and an unusually large CSP may reflect callosal and limbic 
abnormalities specifically (3).   
1.1.2. Anatomy 
The cavum septum pellucidum has the following boundaries: 
 Anteriorly it extends to the genu of the corpus callosum. 
 Superiorly it is bounded by the body of the corpus callosum. 
 Inferiorly, the rostrum of the corpus and the anterior commissure form its 
borders. 
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 Posteriorly, the CSP extends into the anterior limb and pillars of the fornix (8, 9). 
 Laterally the cavum is bounded by the two laminae of the septum pellucidum (9).  
The diagrams below (10) demonstrates the morphology of a brain with a CSP, compared 
to a normal brain without a CSP.  
 
 
Figure 1.1. Diagram demonstrating axial views of a brain with and without a CSP, at the level of 
the frontal horns of the lateral ventricles  
(10) 
(Image by artist, Minette Eiselen; used with permission) 
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Figure 1.2. Diagram demonstrating coronal views of a brain with and without a CSP, at the level 
of the frontal horns of the lateral ventricles 
(10) 
(Image by artist, Minette Eiselen; used with permission) 
 
The CSP is also referred to as “the fifth ventricle”, as it is fluid-filled (11); however there is 
no connection to the ventricles (11, 12).  In the sagittal and coronal planes, the CSP 
appears triangular with its base as the corpus callosum (8, 9).   
The most extreme form of CSP occurs when there is a complete lack of fusion of the two 
septal laminae (13).  This is referred to as a combined cavum septum pellucidum and 
cavum vergae (13).  
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1.1.3. Grading of CSP 
Various grading scales are used for CSP (13).  The most common method referenced in 
the literature involves measuring the anterior-to-posterior length of the cavum on 
consecutive coronal slices, and grading its length into the following categories: 
 1.5 – 4.4 mm: variant 
 4.5 – 5.9 mm: borderline 
 >6mm: enlarged (3, 11, 14, 15), as demonstrated on the selected pre-contrast 
axial and coronal slices of a CT Brain below. 
 
Figure 1.3. Enlarged CSP (axial slice of a pre-contrast CT scan of the brain at the level of the 
frontal horns of the lateral ventricles) 
(16) 
(Source: Chris Hani Baragwanath PACS System; used with permission) 
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Figure 1.4. Enlarged CSP (coronal slice of a pre-contrast CT scan of the brain at the level of the 
frontal horns of the lateral ventricles) 
(16) 
(Source: Chris Hani Baragwanath PACS System; used with permission) 
Due to the lentiform contour of a CSP, it cannot be visualised completely on a single axial 
slice.  Mitigating factors for possible inaccuracy include partial voluming and slice 
thickness, where the latter is specific for MRI (2, 30).  
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1.1.4. Technique of imaging and measurement of CSP 
There is a wide variation in the techniques used for imaging and measurement of CSP 
(13).  The reported prevalence varies between 0.1% and 85% depending on the method 
of identification (11), which includes the use of CT and MRI, as well as 
pneumoencephalography (PEG) and post-mortem examination (11).  PEG sequences 
demonstrate the lowest sensitivity for the evaluation of CSP, while post-mortem studies 
have the highest sensitivity overall (4, 11).  The increase in prevalence of CSP in autopsied 
specimens is theorised to be due to the swelling of the post-mortem septum pellucidum 
which consequently separates into its constituent leaflets and fills with fluid , as well as 
the higher spatial resolution of histology specimens (17). 
Most of the MRI studies in the literature make use of a 1.5 Tesla MRI scanner (13, 18).  
Various sequences are used, namely: 
 3D spoiled GRE steady-state imaging, with axial, sagittal and coronal 
reconstructions (14, 18); 
 3D T1 GRE FLASH with 1mm coronal reconstructions (3). 
There is also a great variation in the slice thickness utilized, ranging from 0.94 mm to 5 
mm (13).  Thick slice studies exhibit a lower yield because the resultant voxel dimensions 
exceed the CSP dimensions, causing a partial volume artefact, thus decreasing sensitivity 
of CSP detection and accuracy of measurement (19).  Consequently thin slice MRI has a 
higher sensitivity for imaging evaluation of CSP (11). 
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MRI data can be obtained as a 3D data set and resampled in 1 mm slices.  The coronal, 
sagittal and axial planes are inspected simultaneously to allow for a thorough 
examination and identification of CSP (3, 14, 18).  
A quantitative measurement technique has been adopted whereby the antero-posterior 
length of the CSP is measured by counting the coronal views (with no gaps) on which it 
appears (3, 13, 18).   The number of slices is then multiplied by their thickness to calculate 
the size of the CSP.  This is the most sensitive and reliable method of classifying CSP (18), 
due to the distinctive sickle-shape of a CSP.   
Neuroimaging with CT scan has higher spatial resolution, albeit  lower contrast resolution 
than MR-imaging (20).  It is also the neuroimaging modality primarily used in the South 
African context due to its availability (21).  Although CT imaging has not been used in 
studies in the literature review, it is the ideal imaging modality for visualising a small 
structure with high intrinsic contrast resolution, such as a CSP (20). 
1.1.5. Causes and Prevalence of CSP 
The prevalence of CSP is controversial. A wide range has been reported, dependant on 
the method of identification, the criteria for CSP characterization and the population 
sampled (1).  The inability to define an accurate prevalence has resulted in further 
uncertainty regarding the significance of a CSP (9). 
The literature does support an increased prevalence of CSP in the following populations: 
 Males (9, 11) 
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 Professional boxers: postulated to be secondary to acceleration-deceleration 
forces causing detachment of the fornix with consequential splaying of the 
forniceal bodies (8) 
 Psychiatric disorders (6, 13, 18) 
1.2. CSP and Psychiatry  
1.2.1. Diagnosis of Psychiatric Disorders 
The basis of psychiatric diagnosis hinges on clinical manifestations of mental illness and 
the categorisation of these symptoms using the Diagnostic and Statistical Manual of 
Mental Disorders (DSM) criteria (22).  According to the DSM-IVR, the differentiation 
between normality and pathology can present a diagnostic challenge, hence the 
conceptualization of the DSM criteria to provide objectivity regarding psychiatric illness 
(23).  Each mental illness is a “clinically significant behavioural or psychological syndrome 
or pattern” that results in “present distress... or disability.... or with a significantly 
increased risk of suffering death, pain, disability or an important loss of freedom” (23).    
The controversial, newly published DSM V (24) demonstrates subtle changes regarding  
the diagnosis of schizophrenia (25).  The crux of the diagnosis of schizophrenia includes 
positive symptoms, namely “delusions, hallucinations, disorganized thinking and 
behaviour”, as well as negative symptoms (the absence of normal emotional function or 
behaviour) present over a continuous 6 month period,  with one month of active 
symptoms (25, 26).  The elimination of causative organic pathology has remained a 
diagnostic criterion (25). 
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Various medical conditions can masquerade as psychiatric pathology, as depicted by the 
table below. This table has been modified from Psychiatric emergencies (part III): 
psychiatric symptoms resulting from organic diseases (27). 
Table 1.1. Organic Disease producing Psychiatric Symptoms 
Disorder Psychosis Depression Mania Anxiety 
Hypopituitarism + - - + 
Hyperprolactinaemia - + - + 
Hypothyroidism + + + + 
Hyperthyroidism + + + + 
Addison’s disease + + - - 
Cushing’s disease + + - + 
Phaeochromocytoma - - - - 
Fluids and electrolyte 
disorders 
+ + - + 
Wernicke-Korsakoff + + + + 
EDH, SDH + + + + 
Cerebral contusion, 
haematoma 
+ + + + 
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Disorder Psychosis Depression Mania Anxiety 
TIA - + - + 
Stroke + + + + 
Meningitis, 
encephalitis 
+ + + + 
Neurosyphilis + + + + 
Degenerative brain 
disease 
+ + + + 
Epilepsy + + + + 
 
The exclusion of organic pathology during psychiatric work-up requires the investigating 
physician to take a detailed history, perform a mental state examination as well as a 
physical examination, and request appropriate investigations (28).  Brain imaging with CT 
or MRI may be performed, if clinically indicated (28). 
1.2.2. CSP and Psychiatric Disorders 
The cavum septum pellucidum (CSP) has been postulated to be a potential marker of 
brain maldevelopment (especially midline abnormalities and limbic system dysgenesis) 
and has been linked with multiple psychiatric disorders (6, 9, 18).  A small CSP is 
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considered a normal variant; however an enlarged CSP may be related to schizophrenia 
(1, 9) amongst other disorders listed below:   
 Schizotypal personality disorder (6) 
 Bipolar disorder (6, 29) 
 Tourette’s Syndrome (6, 7) 
 Obsessive-Compulsive Disorder (6) 
 Mental retardation (14, 30, 31) 
 Developmental delay (14, 31) 
 Seizures (14, 31) 
 Macro/microcephaly (14, 31) 
 The use of illicit drugs, particularly adolescent-onset opiate use (32) 
 Apert’s Syndrome (18) 
 Antisocial personality disorder (33) 
 Psychopathy (33) 
 Fetal alcohol syndrome (13) 
1.2.3. CSP and Schizophrenia 
Within the schizophrenic population, an enlarged CSP has been associated with poor 
verbal learning and memory (14, 31), as well as more severe thought disturbances (5).  An 
increase in CSP length correlated positively with an increase in negative symptoms and 
poorer comprehension of sentences (31).   
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Several studies have associated CSP with specific subcategories of the schizophrenic 
population: 
 Women (12) 
 Chronic patients (15, 17) 
 First episode psychotics (5, 34) 
 Childhood-onset schizophrenics (18) 
 Poor prognosis schizophrenics with a history of long-term institutionalization (5, 
30, 31) 
 An increased rate of successful suicide, especially hanging (35) 
 A family history of psychosis (13). 
Despite this extensive amount of information regarding CSP in schizophrenia, several 
questions remain:  
- What is the role of antipsychotic medication in the structural changes that take place in 
the psychotic brain (13)?   
- Does disease progression influence these morphological abnormalities (36)? 
1.2.4. Aetiology of Schizophrenia  
Schizophrenia is a debilitating psychiatric disease (25), affecting 1% of the population 
worldwide (37).  Despite this, its aetiology remains complex and controversial (38).  An 
interaction between genetic and environmental factors is currently accepted, whereby 
multiple DNA loci and contextual factors interact to increase vulnerability the 
development of schizophrenia (3, 37, 38). 
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Several environmental elements have been implicated in the multifactorial pathogenesis 
of schizophrenia.  These include: perinatal complications, malnutrition, intrauterine 
infections (1, 25), childhood trauma and sexual abuse (39). The incidence of schizophrenia 
has also been shown to be higher in those raised in an urban setting and among minority 
ethnicities (25).  The use of Marijuana is also considered an important aetiological 
component (37) and has been recognised to double the risk of psychosis (39). 
The complex genetic factors involved in an individual’s susceptibility to psychosis are 
considered to be interactive and confer an increased risk of psychosis without being 
causative independently (37).  They may be divided into direct and indirect factors, 
referring to genetic endophenotype and a family history of the disease respectively (39).  
Currently the most accurate indicator of a future diagnosis of schizophrenia or bipolar 
mood disorder is a family history of the disorder, although the exact genetic origins 
remain unknown (37).  The catechol-O-methyl-transferase gene has been linked to an 
increased susceptibility to schizophrenia (39), as well as other hereditary structural 
lesions, which are contributory in familial schizophrenia (37).   
The neurodevelopmental model of schizophrenia is prominently featured in the 
literature, where it has been postulated that brain dysgenesis interacts with normal 
neurodevelopment over a protracted period to result in psychosis (38, 39).  Nopoulos et 
al. in 1998 suggested that the more severe the neurodevelopmental aberrations, the 
younger the age of onset of schizophrenia (18).  Evidence for the neurodevelopmental 
hypothesis is provided in several categories (5): 
 Aetiological: perinatal complications, viral infections of the pregnant mother 
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 Phenotypic: cognitive, behavioural, kinetic, physical pathology pre-psychosis 
 Structural neuropathology: gray matter heterotopias, cavum septum pellucidum 
(5, 15, 17). 
The controversy still remains whether schizophrenia is the result of a physical or 
physiological anomaly (12), though the most likely explanation is a complex interaction of 
deranged structure and dysfunction, neither of which would be sufficient to cause disease 
in isolation (37). 
1.2.5. Structural Correlates of Schizophrenia 
Numerous structural anomalies have been associated with schizophrenia through imaging 
and post-mortem studies (12, 17), although whether they are causative or a consequence 
of the disease remains unclear (15).  In keeping with the neurodevelopmental theory, a 
marker of distorted neurodevelopment (though not necessarily the underlying cause) 
should be evident (15) from birth (18).   
Brain abnormalities associated with schizophrenia in the literature are mainly of limbic 
and midline origin (5), including: 
 Cavum septum pellucidum, especially the enlarged variant which may act as a 
marker for limbic system or midline abnormalities (2, 15, 17, 18), 
 Corpus callosum agenesis/ dysgenesis (9, 15, 18), 
 Gray matter heterotopia (9, 18), 
 Interruptions of the cingulate sulcus (2) with decreased neuronal density (12), 
 Poorly-defined paracingulate sulcus in the left hemisphere (2), 
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 Asymmetrical lateral ventricles (2), 
 Generalised atrophy (2), 
 Disorganised pyramidal cells of the hippocampus (9, 12), 
 Decreased volume of the white matter in the parahippocampal region (3, 12), 
 Decreased volume of amygdala and hippocampus (3, 12), as well as hippocampal 
gliosis (12) which appears more significant in male schizophrenics (4), 
 Cerebellar pathology (14), 
 Decreased gray matter volume (13), 
 Increased third and lateral ventricular volume (9, 13, 17, 38), 
 Arachnoid cysts (13), 
 Absence of the interthalamic adhesion, which interestingly has been associated 
with more severe negative symptoms, longer illness duration and higher 
antipsychotic dosages (38), 
 Gray matter volume loss (13). 
Hippocampal and parahippocampal abnormalities are associated with a higher 
prevalence of positive symptoms in schizophrenia. As such, neurodevelopmental 
anomalies in this region are considered a possible cause for the positive symptoms of 
psychosis (5). 
1.2.6. Schizophrenia in South Africa 
The diverse South African population has a prevalence of schizophrenia similar to the 
reported international prevalence of between 0.3 (25) and 1% (40).  90% of untreated 
schizophrenics reside in developing countries (41), such as South Africa.  Our indigenous 
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epidemiology is quite unique in that the South African Afrikaans community has been 
identified as a founder population with a genetically identifiable aetiology of the disease 
(37, 42). There is a lack of data regarding Black South Africans (43).   
Afrikaners immigrated to South Africa from the Netherlands from 1652 onward, settling 
in the Cape.  The 1000-2000 individuals formed small communities, which remained 
culturally, religiously and geographically isolated over the next 13-15 generations.  The 
increase to the current population of 3 million occurred mainly through reproduction and 
consanguinity early on.    The genetic isolation of the Afrikaners has resulted in a high 
incidence of rare Mendelian disorders, as well as a relatively homogeneous variance of 
associated alleles and the conservation of disease-related haplotypes (42, 44). 
In 2004, Abecasis et al. traced the genotype of 98 Afrikaner individuals diagnosed with 
schizophrenia and traced 87 of them to a common founder ancestor (42). 
An exogenous factor, which is influential in South Africa, is the use of marijuana.  
Cannabis is second only to alcohol as the commonest substance of abuse in South Africa 
(44).  As mentioned previously, the use of cannabis doubles the risk of developing 
schizophrenia (39). 
2. Aim 
This study aims to determine the prevalence of cavum septum pellucidum in mental 
health referrals in South Africa and classify this according to mental health diagnosis. 
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3. Study Objectives 
 to determine the prevalence of CSP in a population of mental health referrals as 
well as in a control population, and to compare the prevalence of CSP in the 
above-mentioned groups 
 to compare diagnostic subcategories of mental health referrals with regards to 
prevalence of CSP 
4. Methods 
4.1. Research Paradigm 
This was a retrospective, observational, cross-sectional study with a control population. 
4.2. Sample 
The study population consisted of mental health referrals presenting for CT Brain scans at 
Chris Hani Baragwanath Academic Hospital over four months. Our sample size was 228 
patients in total, comprised of 114 mental health referrals and an equal number of 
trauma patients, matched for sex and age, as controls. 
4.2.1. Inclusion Criteria 
Adult patients (≥18 years of age) who presented for CT Brain scans as a referral from the 
psychiatry department with a history of psychiatric symptoms for investigation were  
included in the study. Referrals from the emergency department who underwent CT brain 
scans for minor trauma and had no radiological evidence of intracranial injury, were used 
as the controls.  These patients were selected from consecutive trauma referral CT Brain 
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scans to match the mental health referrals for sex and age, and were referred during the 
same period as the study patients. 
4.2.2. Exclusion Criteria 
In order for the radiologists reading images for the study to remain blinded to the study 
cohort, control scans with radiological evidence of acute intracranial injury were excluded 
from the controls by the primary investigator, who reviewed the included scans in the 
controls prior to radiologist readings.   Illegible request forms and control patients with a 
history of mental illness, as described in the request for radiological investigation, were 
excluded from the study by the primary investigator, who accessed this data prior to 
assigning patients in the control group. 
4.3. Materials and Methods 
CT scans were performed using Toshiba Aquilon multidetector CT scanners (Yokohama, 
Japan) with 128 and 64 detector arrays.  The CT Brain scans are performed using a 
standard brain protocol (120kV, 30mAs) with 0.5mm reconstructions on a brain window.  
Data collection included copies of the requisition form and retrieving the DICOM-format 
CT scan on DVD. Images (CT data) from the DVD’s were then reconstructed using Osirix 
(image viewing and manipulation freeware by Apple) into axial, sagittal and coronal 
0.5mm thick slices of the brain by the primary investigator. Patient information was 
anonymised using Osirix software before presenting the images to CT readers. 
Three readers (two radiology registrars in their first two years of specialization and a 
consultant radiologist) interpreted all the CT scans. The radiologists were blinded to the 
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referral information and to each other.  They were asked to independently interpret the 
CT scans according to defined criteria stipulated below, on individual Apple Computers. 
  A ‘final’ decision on the presence of CSP was then made once the primary investigator 
evaluated all three readers’ data sets using a majority rule.  
4.4. Data Collection 
The following data was collected by the primary investigator: 
 Demographics: age and gender. 
 Only history provided by the referring physician on the request forms for CT brain 
scan was used: mental illness, specific diagnosis, treatment-resistance, as well as a 
history of other known contributory factors, such as a history of head injury, 
alcohol and drug abuse, or a family history of mental illness.  
 CT findings were recorded by the three readers was merged into a ‘final decision’ 
based on a majority rule principal for the following: presence or absence of a 
cavum septum pellucidum. 
 The maximum dimensions of the enlarged CSP in the axial and coronal planes 
using digital calipers in the following manner: the ‘CSP length’ was determined by 
three readers (a consultant radiologist and two radiology registrars), using the 
same method as similar studies from the literature (1, 4, 18), namely a 
quantitative measurement in the coronal plane calculating the number of 
consecutive coronal 0.5 mm slices on which a CSP is visible. The maximum axial 
width of the CSP was also measured. In the case of unanimous agreement, all 
three measurements were averaged for statistical analysis. In case of 
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disagreement regarding the presence of a CSP, when the majority decision was 
that it was present, only the measurements made by the two readers in 
agreement were averaged. 
All CSP’s that were considered present were measured; small CSP’s (as depicted in Figure 
4.1 below) which may be considered normal variants, were read as positive despite the 
lack of evidence regarding their significance. 
 
Figure 4.1. Small CSP (axial slice of a pre-contrast CT scan of the brain at the level of the frontal 
horns of the lateral ventricles) 
(16) 
(Source: Chris Hani Baragwanath PACS System; used with permission) 
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4.5. Statistical Analysis 
The relationship between continuous and categorical variables was assessed by the t-test 
(or ANOVA for more than two groups).  Where the data did not meet the assumptions of 
these tests, a non-parametric alternative, the Wilcoxon rank sum test (or the Kruskal-
Wallis test for more than two groups) was used.   The strength of the associations was 
measured by the Cohen’s d-value for parametric tests and the r-value for the non-
parametric tests.   
In determination of predictive factors for CSP within the study population, logistic 
regression was used as CSP is a binary dependent variable.  For this technique, the 
minimum size of the smallest DV class should be 10* the number of independent variable 
parameters to be estimated.  The independent variable list given (age, gender, head 
injury, alcohol abuse, substance abuse, epilepsy, and HIV status) comprised 9 parameters, 
so some variable selection was done.  Family history of mental illness as an independent 
variable was not used, since there were no cases. Given the large number of independent 
variables, and the sample size limitations, univariate logistic regression was first 
performed with each independent variable separately.  Variables with a Wald statistic 
significant at p<0.20 were retained for multiple logistic regression analysis.  
The mental health referrals were then divided according to the types of mental illness 
diagnosed. For the purposes of comparative analysis they were classified in the following 
diagnostic categories: schizophrenia spectrum disorders (which included schizophrenia, 
brief psychotic disorder, substance-induced psychosis); mood disorders (which included 
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bipolar and major depressive disorder); anxiety disorders (which included generalized 
anxiety disorder); and other (which included pseudocyesis and unsure diagnoses).   
Between-group tests were conducted with the following statistical analyses:   
 The Χ2 test was used to assess the relationships between categorical variables.   
 Fisher’s exact test was used for 2 x 2 tables or where the requirements for the Χ2 
test could not be met.   
 The strength of the associations was measured by Cramer’s V and the phi 
coefficient respectively.    
Interrater agreement on the CSP prevalence was determined by raw agreement values, as 
well as Kappa Chance Corrected measure of agreement.  Interrater bias among the three 
raters was determined using Cochran’s Q statistic.  Where analysis involved continuous 
outcomes and all three raters, the Intraclass Correlation Coefficient (ICC) was used to 
calculate the proportion of variability in the data which is attributable to variation 
between patients.   
5. Results 
5.1. Comparisons between the Mental Health Referrals and Controls 
The study comprised a total of 228 patients, consisting of 114 patients making up the 
mental health referrals and 114 patients making up the controls. 
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The mean age of the mental health referrals was 42.5 years (SD = 14.7) and that of the 
controls was 42.5 years (SD = 14.7).  For both groups, the standard deviation was 14.7, 
the median value was 42 and the IQR was 31 – 53.   
The gender distribution in the mental health referrals was 41.23 % males and 58.77 % 
females; that of the controls 41.23 % males and 58.77 % females. There were no 
significant differences between the two groups with respect to age and gender because 
the controls were chosen to match the study group. 
5.1.1. Type of Mental Illness diagnosed in the Mental Health Referrals  
The prevalence of the different types of mental illness in the mental health referrals is 
shown in Figure 5.1.  Note that the percentages do not sum to 100% since some patients 
had more than one type of mental illness.  Schizophrenia spectrum predominated 
(79.0%). 
 
Figure 5.1. Distribution of different types of Mental Illnesses in the Mental Health Referrals 
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5.1.2. Prevalence of CSP in the Mental Health Referrals and Controls 
42 of the 114 mental health referrals, comprising 36.8% (95% CI: 28.0-46.4%) of the 
group, had a CSP.  By comparison, 28 of the 114 controls had a CSP comprising 24.6% 
(95% CI: 17.0-33.5%) of the group (Figure 5.2).  The difference was not significant 
(p=0.06). 
 
Figure 5.2. Prevalence of CSP in the Mental health referrals and Controls 
 
Interrater Agreement 
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Table 5.1. Rater’s Determination of CSP Prevalence 
Rater 
Number of patients read 
as having a CSP 
Percentage of patients read 
as having a CSP 
A 66 28.95 
B 68 29.39 
C 73 31.58 
 
The kappa chance-corrected measure of agreement was 0.88, which corresponds to 
‘almost perfect’ agreement (Table 5.2).  The Cochran’s Q statistic was not significant 
(p=0.16), indicating that there was no significant bias between the raters in determining 
the presence or absence of CSP. Although the agreement was very good and there was no 
significant bias, the agreement and bias between each pair of raters was determined.  The 
agreement between all pairs of raters was high.  There was no significant bias between 
any pair of raters. 
Table 5.2. Interrater Agreement 
Raters Kappa 
95% confidence 
interval for kappa 
Interpretation of 
kappa 
p-value for McNemar's 
test 
A vs. B 0.88 0.82-0.95 
almost perfect 
agreement 
0.76 
A vs C 0.88 0.81-0.94 
almost perfect 
agreement 
0.083 
B vs C 0.89 0.82-0.95 
almost perfect 
agreement 
0.13 
5.1.3. Anteroposterior Length of CSP in the Mental Health Referrals and 
Controls  
The median anteroposterior length was 15.3 mm and 13.9 mm for the mental health 
referrals and controls respectively.  The difference was not significant (p=0.39). 
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The mean and median anteroposterior lengths of CSP for the mental health referrals and 
controls, as well as the standard deviation and interquartile range are demonstrated in 
Table 5.3. 
Table 5.3.  CSP Anteroposterior Length Statistical Analysis 
AP length analysis Mental Health Referrals Controls 
Mean 25.38 17.01 
Median 15.3 13.9 
Standard deviation 26.67 9.66 
IQR 10.67 – 32.33 9.42 – 23.83 
 
Interrater Agreement 
The kappa chance-corrected measure of agreement was 0.90 for determination of CSP 
anteroposterior length indicating ‘almost perfect’ agreement between the three raters, as 
demonstrated in Table 5.4.  
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Table 5.4. Assessment of Anteroposterior Length 
Variable A B C 
Number of 
patients read 
as having a 
CSP 
66 68 73 
Mean AP 
length 
25 23 20 
Std Dev AP 
length 
27 20 22 
Median AP 
length 
16 15 14 
Interquartile 
range of AP 
length 
10 12 10 
28 31 18 
Minimum AP 
length 
3 3 5 
Maximum AP 
length 
138 110 123 
 
5.1.4. Axial Width of CSP in the Mental Health Referrals and Controls 
The median axial width of CSP was 1.8 and 2.6 mm for the controls and mental health 
referrals respectively.  The difference was significant (p=0.046), with a small effect size 
(r=0.24).  The statistical analysis of axial widths is shown in Table 5.5.  
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Table 5.5. Statistical Analysis of Axial Width of CSP in Mental health referrals and Controls 
Axial width analysis Mental health referrals Controls 
Mean 3.85 2.51 
Median 2.55 1.75 
Standard deviation 3.12 1.81 
IQR 1.75 – 5.60 1.23 – 4.07 
 
Interrater Agreement 
In measurement of CSP axial width, the agreement between all pairs of raters was 
excellent, as depicted in Table 5.6. 
Table 5.6. Interrater Agreement in Assessment of Axial Width   
Variable A B C 
Number of 
patients 
read as 
having a 
CSP  
66 68 73 
Mean axial 
width 
3.8 3.3 3.1 
Std Dev of 
axial width 
3.3 2.7 2.7 
Median 
axial width 
2.3 2.4 2.3 
Interquartile 
range of 
axial widths 
1 2 2 
6 5 4 
Minimum 
axial width 
0 0 1 
Maximum 
axial width 
16 17 16 
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5.2. Comparison of Prevalence of CSP in the Mental Health 
Subgroups 
For the purposes of comparative analysis the patients in the mental health referrals were 
classified in the following diagnostic categories: schizophrenia spectrum disorders (which 
included schizophrenia, brief psychotic disorder, substance-induced psychosis); mood 
disorders (which included bipolar and major depressive disorder); anxiety disorders 
(which included generalized anxiety disorder); and other (which included pseudocyesis 
and unsure diagnoses). 
5.2.1. Prevalence of CSP in the Mental Health Subgroups 
In the schizophrenia spectrum subgroup 36 of 90 patients, comprising 40.0% (95% CI: 
29.8-50.9%) of the group, had a CSP.  By comparison, 6 of 24 mental health referrals 
who did not have a schizophrenia-spectrum disorder, had a CSP, comprising 25.0% 
(95% CI: 9.8-46.7%) of the non-schizophrenia spectrum subgroup.  The difference 
was not significant (p=0.24). 
In the mood disorder subgroup, 7 of 24 patients had a CSP.  This is calculated as 29.2% 
(95% CI: 12.6-51.1%) of the patients in the mood disorder subgroup, compared to 35 of 
90 patients in the non-mood disorder subgroup, which comprises 38.9% (95% CI: 28.8-
49.7%) of this subgroup. The difference was not significant (p=0.48).   
The prevalence of CSP in these groups is demonstrated in Figure 5.3. 
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Figure 5.3. CSP prevalence in Mental Health Subgroups 
 
5.2.2. Anteroposterior Length of CSP in the Mental Health Subgroups 
The median anteroposterior length of CSP was 15.3 mm and 16.0 mm for the 
schizophrenia spectrum and non-schizophrenia spectrum subgroups respectively.  The 
difference was not significant (p=0.75).  The statistical analysis of the anteroposterior 
length of CSP is demonstrated in Table 5.7.   
Table 5.7. The Statistical Analysis of CSP Anteroposterior Length in the Schizophrenia-Spectrum 
Subgroups 
AP length analysis 
Schizophrenia Spectrum 
Subgroup 
Non-Schizophrenia Spectrum 
Subgroup 
Mean 26.19 20.56 
Median 15.33 16.00 
Standard 
deviation 
28.53 10.09 
IQR 9.67 – 31.33 13.33 – 32.33 
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The median anteroposterior length was 13.3 mm and 16.0 mm for the mood disorder and 
non-mood disorder subgroups respectively.  The difference was not significant (p=0.32).  
The statistical analysis of the anteroposterior length of CSP is demonstrated in Table 5.8. 
Table 5.8. The Statistical Analysis of CSP Anteroposterior Length in the Mood Disorder 
Subgroups 
AP length analysis Mood disorder Subgroup Non-Mood disorder Subgroup 
Mean 25.17 25.42 
Median 13.33 16.00 
Standard deviation 37.54 24.68 
IQR 9.00 - 18.00 11.33 – 32.67 
5.2.3. Axial width of CSP in the Mental Health Subgroups 
The median axial width was 5.2 and 2.2 mm for the non- schizophrenia spectrum and 
schizophrenia spectrum groups respectively.  The difference was significant (p=0.049), 
with a small effect size (r=0.31).  The statistical analysis of the axial width of CSP is 
demonstrated in Table 5.9. 
Table 5.9. The Statistical Analysis of CSP Axial Width in the Schizophrenia-Spectrum Subgroups 
Axial width 
analysis 
Schizophrenia Spectrum 
Subgroup 
Non-Schizophrenia Spectrum 
Subgroup 
Mean 3.61 5.34 
Median 2.18 5.20 
Standard 
deviation 
3.20 2.23 
IQR 1.70 – 4.47 4.07 – 6.50 
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The median axial width was 3.7 and 2.0 mm for the non-mood disorder and mood 
disorder groups respectively.  The difference was not significant (p=0.22).  The statistical 
analysis of the axial width of CSP is demonstrated in Table 5.10. 
Table 5.10. The Statistical Analysis of CSP Axial Width in the Mood Disorder Subgroups 
Axial width analysis Mood disorder Subgroup Non-Mood disorder Subgroup 
Mean 3.48 3.93 
Median 2.03 3.73 
Standard deviation 4.41 2.88 
IQR 1.00 – 3.73 1.77 – 5.63 
5.2.4. Predictive Clinical Factors for CSP within the Mental Health Referrals 
There were no variables (HIV status, drug use, family history of mental illness) which were 
significant even at p<0.20 and thus we did not proceed to multiple logistic regression 
analysis.  None of the independent variables were significant predictors of CSP within the 
mental health referrals. 
6. Discussion 
This study found no statistically significant difference in the prevalence of CSP in patients 
with mental illness (36.8%) compared to those with no mental illness (24.6%). The 
prevalence of CSP represented in the literature varies from 9.30% (45) to 85.10% (3) for 
mental health patients, and from 2% (17) to 85.7% (46) for controls.  Our results of 36.8% 
and 24.6% respectively, are within this wide range, and are most similar to DeLisi’s study 
of 1993 (15) and Fukuzako’s research in 1998 (47).  DeLisi had a total population of 132 
(85 schizophrenic patients, 47 control patients) with CSP noted in 44.7% of schizophrenics 
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and 29.8% of control patients (15) .  Fukuzako had a total population of 113 patients (72 
schizophrenic patients and 41 control patients) with results of 47.2% and 38% 
respectively (47).  A meta-analysis by Trzesniak in 2011 determined that a CSP of any size 
is not found more frequently in schizophrenic patients (13), and our findings are in 
agreement with this. 
Further, this study found no significant difference in the prevalence with respect to the 
different types of mental illnesses (schizophrenia-spectrum group and mood disorder 
group).  There are very few other studies that considered a comparative analysis of 
multiple mental illnesses.   Kwon evaluated the prevalence of CSP in 67 mental health 
patients, including 30 schizophrenic patients, 16 affective disorder patients and 21 
schizotypal disorder patients, which were compared to each other and 46 control 
patients, and did not find a difference in the prevalence of CSP between the four groups 
(48).  However, he subsequently compared “abnormal” CSP prevalence (measuring 6mm 
or more in anteroposterior length) and found a statistically significant increase of CSP 
prevalence in schizophrenic patients, compared to controls (48).  Takahashi has compared 
the prevalence of CSP in schizophrenics and patients with schizotypal disorder (3), as well 
as patients with first-episode psychosis to patients with chronic schizophrenia and 
asymptomatic individuals at ultra-high risk for schizophrenia due to genetic predisposition 
(45).  He did not find a difference in the prevalence of CSP between these groups (3, 45). 
There was no statistically significant difference in median anteroposterior length in the 
mental health referrals (15.3mm) compared to the controls (13.9mm) and with respect to 
the different forms of mental illnesses (schizophrenia spectrum subgroup and mood 
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disorder subgroup).  Trzeniak’s meta-analysis determined that only a large CSP is  more 
common in schizophrenia-spectrum patients (13). Trzeniak’s  research contradicts the 
studies by Crippa (46), Flashman (31), Hagino (30) and Rajarethinam (19) which 
demonstrated findings similar to ours.   
The median anteroposterior lengths for the controls and mental health referrals were 
much larger than those found in previous studies.  This is most likely due to the higher 
spatial resolution of CT used in our study, compared to MRI and direct visualisation used 
in other earlier studies.  The median length was 15.5 mm in the mental health referrals 
and 13.9 mm in the controls.  The conventional parameters for an abnormally large CSP 
(i.e. more than 6 mm) could not be applied to our study, as 96% of the CSP’s identified 
overall were longer than 6mm.   
There is a statistically significant difference (p=0.046) with a small effect size (r=0.24) in 
the median axial width in the mental health referrals (2.6mm) and the controls (1.8mm) 
and a significant difference (p=0.049), with a small effect size (r=0.31) between the non-
schizophrenia spectrum and schizophrenia spectrum subgroups.  This significance of CSP 
width, though not as well documented as CSP length, has been noted in previous research 
both in conventional imaging as a volume measurement of CSP, (1) and on post-mortem 
samples as an axial width measurement (35).  These studies determined that CSP width 
was increased in patients with schizophrenia-spectrum disorders (1, 35).   
There were no clinical variables which were significant predictors of the presence of CSP, 
though this finding was limited by poor history supplied on the radiology requisition 
forms. 
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6.2. Results in context 
This study was larger than the average sample populations reported in the literature, with 
114 control patients and 114 study patients comprising at total of 228 individuals.  The 
average size of studies included in the literature review is 150 individuals, with the 
smallest study comprising only 42 patients, and the largest 479 individuals (Appendix B).  
Of these studies, the report by Chon et al in 2010, matched study and control groups for 
sex and age whilst determining CSP prevalence in patients with obsessive compulsive 
disorder (6), as did Crippa et al in 2004 while doing similar research in patients with panic 
disorder (46) and in 2006, when he investigated the association between CSP and 
schizophrenia (1).  The vast majority of studies, however, did not match the study and 
control groups for age and sex. 
The main difference of note between the current research and previous research is the 
use of CT scan as the primary neuroimaging modality for psychiatric work-up compared to 
MRI, pneumoencephalography or post-mortem studies, as used in previous studies. This 
is advantageous in our context because of the relative widespread availability of CT scan 
compared to MRI.  Furthermore, CT imaging is of a higher spatial resolution (albeit lower 
contrast resolution) than MRI (20), accounting for the increased CSP length measured in 
this study compared to previous research.   
The current study is one of the few studies measuring the axial width of CSP’s as a 
possible predictor of mental illness, a difference which was statistically significant 
between mental health referrals and healthy controls.  Previously, only Filipovic 
consistently measured CSP width and advocated its use as a marker for mental illness 
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(35).  Other studies have attempted volumetric CSP measurements (1), but this is much 
less common than CSP length measurements (13).   
Due to the poor history supplied by referring clinicians regarding HIV status, drug use and 
previous head trauma, the multi-variant analysis performed was not performed.  In the 
South African context where these three factors are ubiquitous, their influence in mental 
illness aetiology is possibly underestimated.  
6.3. Current applications  
The presence and length of CSP is not a reliable predictor of the diagnosis of a mental 
illness or a determinant of the type of mental illness diagnosed in our population.  CSP 
width is a statistically significant determinant of mental illness, especially schizophrenia-
spectrum disorders, and can be used as an independent marker of mental illness. This is a 
simple linear measure performed very quickly using callipers on CT scans but the ideal 
location for standardised measurement needs to be defined.  Further prospective studies 
measuring CSP width are recommended with clear clinical definitions and workup to 
accompany the imaging interpretations. 
6.4. Limitations of the current study 
The largest limitation of the study is the use of trauma patients as the controls, as trauma 
has been associated with an increased prevalence of CSP (49).  However, trauma patients 
with moderate or severe trauma, or radiological evidence of trauma, were excluded as 
control patients. 
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The main source of data regarding the patient’s history and illness was provided by the 
radiology requisition form, which is often poorly completed especially in the emergency 
setting   Thus there was a paucity of information regarding both diagnosis and history for 
study and control patients. 
A further limitation was the incorrect registration of patients on the PACS system, which 
created difficulty in tracing the referral route of our patients.   
The resource-limited South African medical environment severely hampers the adequate 
work-up of patients from the periphery due to transport and financial constraints, which 
may have biased the mental health referrals towards those with a higher socio-economic 
status who could afford transport.  
The retrospective nature of the research caused a bias, as predominantly schizophrenic 
mental health referrals are investigated by imaging.  Prospective work could include a 
more representative population of mental health referrals, with equal numbers of 
patients in the mental health subgroups to better investigate the prevalence of CSP in all 
the diagnostic categories of mental illness. 
6.5. Future applications  
The axial width of a CSP is a reproducible, single-step measurement, and is therefore 
simpler and faster than calculating the anteroposterior length of CSP by multiplying the 
number of reformatted coronal slices on which the CSP appears with the slice thickness.  
Axial width measurements could become routine on all CT Brain scans.  The use of CSP 
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axial width could be utilised by CAD software to automatically measure the CSP width and 
highlight the abnormality as a potential marker of mental illness.   
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7. Conclusion 
Our study aimed to determine the prevalence of CSP in mental health referrals and 
normal patients.  Our study varied from previous published works in the use of CT as the 
primary investigation for brain imaging, as well as the measurement of CSP width.  There 
was no statistically significant association noted between the prevalence or length of CSP 
and psychiatric diagnosis.  The axial width of the CSP was a statistically significant 
predictor of mental illness.  Further research evaluating CSP length and width is 
recommended.  The length of CSP’s in this study was larger than in previous studies, 
demonstrating either a larger baseline length in the South African population, or as a 
result of using CT as our imaging modality. 
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Appendix B: Comparison of the Current Study to Literature Review of CSP and Mental Illness 
Year Author Imaging Method 
Total 
patients 
Mental health 
group and 
diagnosis 
Controls 
CSP in mental health 
patients (Unless otherwise 
stated, refers to CSP of any 
size) 
CSP in 
controls 
2008 Choi MRI 87 
30 ultra high-risk for 
schizophrenia 
34 
21/30 
(70.0%) 
ultra high-
risk 
Abnormal 
CSP ( Grade 
2,3, 4) 
13/34 (38.2%) 
23 genetic high-risk 
for schizophrenia 
12/23 
(52.2%) 
genetic 
high-risk 
2010 Chon MRI 142 
71 Obsessive-
compulsive disorder 
71 
Matched 
for sex 
and age 
16/71 
(22.5%) 
Abnormal 
CSP ( Grade 
2,3, 4) 
10/71 
(14.1%)  
2004 Crippa MRI 42 21 Panic disorder 21 
Matched 
for sex 
and age 
16/21 (76.2%)  
18 / 21 
(85.7%) 
2006 Crippa MRI 76 38 schizophrenia 38 
Matched 
for sex 
and age 
30/38 (78.9%)- CSP of any 
size 
33/38 
(86.8%)- CSP 
of any size 
8/38 (21.1%) – CSP>6mm 
1/38 (2.6%) 
– CSP>6mm 
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Year Author Imaging Method 
Total 
patients 
Mental health 
group and 
diagnosis 
Controls 
CSP in mental health 
patients (Unless otherwise 
stated, refers to CSP of any 
size) 
CSP in 
controls 
1993 DeLisi MRI 132 85 schizophrenia 47 
Matched 
for age 
38/85 (44.7%) 
14/47 
(29.8%). 
1992 DeGreef MRI 108 62 schizophrenia 46 14/62 (23%) 1/46 (2%) 
1992 DeGreef 
MRI 127 81 schizophrenia 46 17/81 (21%) 1/46 (2%) 
Post-mortem 
studies 
67 28 schizophrenia 39 17/28 (61%) 12/39 (31%) 
2005 Filipovic 
Post-mortem 
studies 
479 30 schizophrenia 377 25/30 (83.33%) 
4/377 
(10.61%) 
2007 Flashman MRI 122 
77 schizophrenia 
spectrum 
55 53/77 (68.8%) 42/55 (76.4%) 
1998 Fukuzako MRI 113 72 schizophrenia 41 34/72 (47.2%) 16 / 41 (38%) 
2004 Galarza MRI 
51 
(females 
only) 
32 schizophrenia 19 14/32 (43.75%) 2/19 (10.52%) 
2001 Hagino MRI 165 86 schizophrenia 79 64/86 (74.40%) 
59/79 
(74.70%) 
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Year Author Imaging Method 
Total 
patients 
Mental health 
group and 
diagnosis 
Controls 
CSP in mental health 
patients (Unless otherwise 
stated, refers to CSP of any 
size) 
CSP in 
controls 
2013 Hwang MRI 132 
65 opiate-
dependent subjects 
67 
54/65 (83.1%) – any CSP   
12/65 (18.5%) – large CSP 
(>6mm) 
43/67 
(64.2%)- any 
CSP 
 
4/67 (6.0%) – 
large CSP 
(>6mm) 
2004 Kasai MRI 130 
33 schizophrenia  
56 
23/33 (69.7%) 
schizophrenia 
49/56 (87.5%) 
41 affective 
psychosis 
33/41 (80.5%) affective 
psychosis 
2003 Kim MRI 
161 
97 children with 
Tourette's 
Syndrome 
64 children 44/97 children (51%) 
43/64 
children (67%) 
107 
43 adults with 
Tourette’s 
Syndrome 
64 adults 16/43 adults (37%) 
38/64 adults 
(59%) 
2007 Kim MRI 82 
41 bipolar mood 
disorder 
41 
8 /41 (19.5%) – large CSP 
(>6mm) 
1/41 (2.4%) – 
large CSP 
(>6mm) 
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Year Author Imaging Method 
Total 
patients 
Mental health 
group and 
diagnosis 
Controls 
CSP in mental health 
patients (Unless otherwise 
stated, refers to CSP of any 
size) 
CSP in 
controls 
1998 Kwon MRI 113 
30 schizophrenia 
46 
23/30 (76.7%) – any CSP                   
7/23 (30.4%) -  large CSP 
(>6mm) 
39/46 
(84.8%)– any 
CSP  
16 affective 
disorder 
10/16 (62.5%)– any CSP                      
2/10 (20%)-  large CSP 
(>6mm) 
4/39 (10.3%)-  
large CSP 
(>6mm) 
21 schizotypal 
disorder 
16/21 (76.2%)– any CSP                      
3/16 (18.8%)-  large CSP 
(>6mm) 
  
1997 Nopoulos MRI 130 55 schizophrenia 75 
32/55 (58.8%)- any CSP       
6/29 (21.0%) – large CSP 
44/75 (58.7%) 
– any CSP   
1/39 (3.0%) – 
large CSP 
1998 Nopoulos MRI 119 
24 adolescents with 
schizophrenia 
95 adolescents 
12.5% (3/24) – large CSP 
(>6mm) 
1.1% (1/95) – 
large CSP 
(>6mm) 
2010 Raine MRI 87 
19 with CSP, 68 
without CSP 
None 
Increased antisocial 
personality disorder and 
psychopathy scores in pt's 
with CSP 
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Year Author Imaging Method 
Total 
patients 
Mental health 
group and 
diagnosis 
Controls 
CSP in mental health 
patients (Unless otherwise 
stated, refers to CSP of any 
size) 
CSP in 
controls 
2001 Rajarethinam MRI 116 73 schizophrenia 43 
3/73 (4.1%) -large 
CSP>6mm 
1/43 (2.3%) – 
large CSP 
(>6mm) 
44/73 (60.3%) -any CSP 
18/43 (41.9%) 
– any CSP 
2008 Rajarethinam MRI 273 
89 schizophrenia 
120 
(60/89) 64% 
77/120 
(64.20%) 64 genetic high-risk 
for schizophrenia 
(41/64) 64.60% 
2007 Takahashi MRI 364 
154 schizophrenia 
163 
117/154 (76.00%) - any CSP   
10/154 (6.5%) - large CSP 
133/163 
(81.60%) - any 
CSP 
47 schizotypal 
disorder 
40/47 (85.10%) - any CSP     
5/47 (10.6%) - large CSP 
12/163 (7.4%) 
- large CSP 
2008 Takahashi MRI 384 
162 first episode 
psychosis 
87 
15/162 (9.30%) 
10/87 
(11.50%) 
89 chronic 
schizophrenia 
10/89 (11.20%) 
135 ultra high-risk 15/135 (11.10%) 
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Year Author Imaging Method 
Total 
patients 
Mental health 
group and 
diagnosis 
Controls 
CSP in mental health 
patients (Unless otherwise 
stated, refers to CSP of any 
size) 
CSP in 
controls 
2014 Jacobs CT 228 
90 Schizophrenia 
spectrum 
114 
42/114 (36.84%) 
28/114 
(24.56%) 
24 Mood disorder 
36/90 (40%) Schizophrenia 
spectrum 
  
7/24 (29.17%) Mood 
disorder 
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